Immunomodulatory nanofilaments are provided which present immune factors, especially cytokines, to immune cells, particularly T cells, so as to modulate the immune response of said cells. Methods of using such nanofilaments are also provided.

Corticosteroid compositions including a corticosteroid drug substance (e.g., fluocinolone, fluocinolone acetonide, dexamethasone, dexamethasone phosphate, dexamethasone sodium phosphate, triamcinolone, and triamcinolone acetonide) or a or a salt or derivative thereof and one or more irregular-shaped particulate fatty acid or keto-enol tautomer complexation agents admixed in a dispersal medium, having a release profile with one or more phases of drug release. These compositions are extended release corticosteroid compositions may release a clinically useful level of corticosteroid for more than 1 to 12 months within the body. Also described herein are methods of forming and methods of using these compositions.

Provided herein are nanofibres including self-assembled cellular components derived from a homogenized plant tissue. Methods for preparing such nanofibres, as well as uses thereof in the treatment or prevention of diseases or disorders in a subject and/or as delivery vehicles are also described.

A complex includes an amyloid peptide complexed with a cholinesterase inhibitor, an NMDA receptor antagonist, or a combination, of a cholinesterase inhibitor and an NMDA receptor antagonist, wherein the amyloid peptide comprises X.sub.1X.sub.2GAIIGX.sub.3X.sub.4 (SEQ ID NO: 2), wherein X.sub.1 and X.sub.4 are each independently YF or FY, and X.sub.2 and X.sub.3 are each 1 amino acid long, and are each independently T, N, S, or Q; or X.sub.2 and X.sub.3 are each 2 amino acid long and X.sub.2 is (Y or F)T, (Y or F)N, (Y or F)S or (Y or F)Q, and X.sub.3 is T(Y or F), N(Y or F), S(Y or F) or Q(Y or F), wherein the amyloid peptide self-assembles into amyloid fibrils, and wherein the peptide has a total length of 11-13 amino acids.

Methods of preparing a functionalized nanofiber preparing a dispersion of a polymer and a water soluble synthetic construct of the structure F-S-L in admixture in a liquid medium; and then electrospinning the polymer from the liquid medium to provide the functionalized nanofiber. F is the functional moiety, L is a lipid and S is a spacer linking F to L via covalent bonds.

The invention relates to creped prebiotic tissue products. The tissue products comprise prebiotics in sufficiently high amounts to have a prebiotic effect in use, without negatively affecting tissue product properties, such as tensile strength, stiffness or softness. Thus, in certain embodiments the present invention provides soft, durable creped prebiotic tissue products that are able to improve the growth of healthy bacteria such as Bifidobacterium spp. or Lactobacillus spp. without promoting growth of enteropathogenic bacteria. The tissue products provide these benefits yet have a GMT greater than about 500, a Stiffness Index less than about 20 and a TS7 value less than about 10.

A drug carrier and a method of using the same are provided, wherein the drug carrier includes a base made of a carbon fiber which is magnetic and has a first polarity, a positioning member connected to the base, and is adapted to be positioned and move to a target location by guiding of at least an energy field, and a connector connected to the positioning member and a drug with two ends respectively, wherein the connector has a second polarity opposite to the first polarity, and is recognized by an organism and digested in the organism. The method includes the steps of: injecting the drug carrier into an organism; positioning the drug carrier to a target location within the organism by an equipment; and releasing the drug from the drug carrier by an external energy.

The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.

The invention relates to creped prebiotic tissue products. The tissue products comprise prebiotics in sufficiently high amounts to have a prebiotic effect in use, without negatively affecting tissue product properties, such as tensile strength, stiffness or softness. Thus, in certain embodiments the present invention provides soft, durable creped prebiotic tissue products that are able to improve the growth of healthy bacteria such as Bifidobacterium spp. or Lactobacillus spp. without promoting growth of enteropathogenic bacteria. The tissue products provide these benefits yet have a GMT greater than about 500, a Stiffness Index less than about 20 and a TS7 value less than about 10.

The invention relates to creped prebiotic tissue products. The tissue products comprise prebiotics in sufficiently high amounts to have a prebiotic effect in use, without negatively affecting tissue product properties, such as tensile strength, stiffness or softness. Thus, in certain embodiments the present invention provides soft, durable creped prebiotic tissue products that are able to improve the growth of healthy bacteria such as Bifidobacterium spp. or Lactobacillus spp. without promoting growth of enteropathogenic bacteria. The tissue products provide these benefits yet have a GMT greater than about 500, a Stiffness Index less than about 20 and a TS7 value less than about 10.